FDA warned Garland, Texas-based American Chinese Natural Herbs, Inc. about adulterated (legally unsafe) dietary supplements made without required manufacturing controls and with mislabeled products.
What happened
FDA inspected the company’s Garland, Texas facility from February 15, 2022 through March 17, 2022 and reviewed product labels. It found missing ingredient and finished-product specifications, missing or incomplete manufacturing records, and inadequate complaint and quality-control procedures. FDA also found many labels were misbranded, including missing Supplement Facts, wrong ingredient names or plant parts, and amounts that did not match the Supplement Facts panel, and it questioned an ingredient listed as water lavage because synonyms point to a poisonous plant.
What FDA found
The company did not set identity specifications for ingredients such as American ginseng, oyster, ginger, and other herbs used in its supplements.
21 CFR 111.70(b)The company did not set finished-product specifications for identity, purity, strength, composition, or contamination limits; FDA said feel, color, and photos cannot confirm identity.
21 CFR 111.70(e)Master manufacturing records lacked required details, and the company did not prepare batch production records for every batch or keep complete records of yields, tests, initials, and quality-control release.
21 CFR 111.210, 111.255(a), 111.260The complaint policy did not require review and investigation of every complaint, and quality control had no written procedures for deciding what to do with each finished lot.
21 CFR 111.553, 111.560(a), 111.103Many labels were misbranded: they missed Supplement Facts or dietary supplement identity, used nonstandard ingredient names, omitted plant parts, did not repeat required information in both languages, or stated amounts that did not match the Supplement Facts.
21 U.S.C. § 343; 21 CFR 101.36, 101.4, 101.3(g), 101.15(c)For Thorough Wax Extract, FDA questioned the ingredient listed as water lavage because its synonyms include water hemlock or hemlock water dropwort, which correspond to a poisonous plant, and asked for its Latin name, identity specification, supplier certificate of analysis, and identity testing.
21 U.S.C. § 343(i)(2); 21 CFR 101.4
What FDA wants
FDA asks the company to correct the cited CGMP and labeling violations and to provide adequate documentation for its corrective actions, including specifications, records, procedures, and label corrections. The provided letter does not state a response deadline.
Who should pay attention
- brands that buy herbal supplements from contract manufacturers
- retailers selling botanical dietary supplements
- quality teams checking ingredient identity and labels
This is a summary. Read the original letter on fda.gov.